In London the morning of 1 December was foggy, frosty and unwelcoming. The rush hour crowds were more than usually surly; the birds were not singing; a bleak day ahead. All the more reason to leave for Colchester where, at the Essex County Hospital, we were warmly greeted by Roger Motson and Douglas Millar, the organizers and hosts of a coloproctology teaching day. These teaching days are designed partly to bring the finer points of the specialty to general surgeons and physicians, and partly as an update for all. The subjects dealt with at this meeting were non surgical aspects of Crohn's disease, anal sphincter injuries and rectal prolapse.
Introducing the first session on non-surgical aspects of Crohn's disease Dr Russel Cowan (Colchester) reminded us of the problems that still remain in the management of such a variable and elusive disease. There are those who advocate dietary treatment and those who favour drugs.
Dr John Hunter (Addenbrookes Hospital) discussed the possibilities of dietary therapy, not as a supportive, but as a specific treatment for both the acute phase of the disease and for maintaining remission. The administration of an elemental diet (E028) used for up to 4 weeks achieves remission in 90% of cases. Having got the patient into remission it is then possible to re-introduce foods slowly in order to identify individual food sensitivities, the commonest being wheat, corn and milk. Given the correct selective diet, it is possible to gain complete control of all aspects of the disease, even uveitis and arthritis, and to have long-term remission. The procedure, however, is time-consuming and tedious for both patient and doctor, and compliance is sometimes poor. Furthermore, selective diets are usually expensive and socially inconvenient. Crohn's disease is probably not due to a food allergy as such, there being no abnormality of immunoglobulins, but more an intolerance to certain foods.
Drug therapy is more conventional and the current situation was presented by Dr Humphrey Hodgson (Hammersmith Hospital), who stressed the problems presented by a disease with varying symptoms. For treatment of active disease steroids are of course effective. Newly developed, poorly absorbed steroids such as fluticasone may well have an important part to play in the future. Azathioprine is of no proven value in active disease, but aminosalicylates may help mild colonic disease. Once remission has been achieved then low dose steroid is probably the only effective treatment for preventing relapse, although azathioprine is of value in that it allows a smaller maintenance dose of steroid to be effective. It is important to note that no drug is effective in maintaining remission if introduced while the disease is inactive. The use of antibiotics has proved disappointing. Metronidazole is occasionally helpful in the short term, but is oflimited value. Antituberculous therapy has not yet proved to be of any value.
A disease of unknown aetiology will always present a therapeutic problem and it was, therefore, interesting to hear Professor John Hermon Taylor (St George's Hospital) give us a progress report on his studies of a possible aetiology. Crohn's ileocolitis in humans is histologically similar to ileocolitis in cows except for the visible presence of mycobacteria in cows. Mycobacteria can only be isolated from human Crohn's disease tissue after prolonged incubation over 1.5-4 years. DNA finger printing of three such isolates showed that they were identical to bovine paratuberculosis, thus returning to the possibility suggested by Dalziel in 1913, that M. paratuberculosis may be involved in Crohn's. Molecular biology is beginning to add to the suggestions that Crohn's disease may be due to mycobacteria whose identification is not possible by conventional means. Theories of infective causes for Crohn's disease come and go like Paris fashions. Maybe this one will stay; maybe not.
The second session, on Anal Sphincter Injuries, was chaired by Mr James Thomson (St Mark's Hospital). Ultrasound nowadays gets into every nook and cranny of the body and the anus is no exception. Dr Penelope Law (St Bartholomew's Hospital) has been using it to image the anal sphincters, and she demonstrated to us how clearly ultrasound can assess the integrity of the internal anal sphincter, and can also map defects in the external sphincter.
Having identified a sphincter defect then direct sphincter repair is the ideal treatment. Mr Roger Motson (Colchester) described the technique, which he then demonstrated with a video. He stressed the importance of generously overlapping the cut ends of the sphincter before suturing them together.
When repair is impossible, as after an abdominoperineal excision, then the use of another muscle, transplanted to surround the anus, has always seemed inviting. Results in the past have been disappointing mainly because of the different nature of somatic voluntary muscle and sphincter muscle. Somatic muscle fibres give rapid type 2 contractions, whereas a sphincter needs a muscle with slow type 1 contractions. Professor Norman Williams (The London Hospital) described how chronic electrostimulation can convert type 2 muscle to type 1. Following studies in dogs using the Sartorius muscle, he has now been using the Gracilis muscle in humans. Chronic electrostimulation seems to have successfully converted the muscle to type 1, and he reported initial promising results for the technique, which clearly holds interesting possibilities for the future.
In the afternoon Mr Geoff Oates (Birmingham) chaired the session on treatment of rectal prolapse. Six different speakers presented six different operations. All six operations can cure rectal prolapse, but all are liable to be followed by continuing problems of constipation or incontinence. So what should we learn from this? Firstly it is clear that there is probably no single procedure suitable for all patients; it is also clear that abdominal repairs are well tolerated even in the very old, and that pre-existing problems of bowel habit are likely to persist after repair. Finally we saw, on video, and learnt what an elegant operation Delorme's procedure can be in the hands of Mr Tom Brennan (Leeds).
An extremely difficult X-ray quiz had been set by Dr Martin Gould for the Nordic registrar's prize. This was won by Peter MacDonald. Several
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Neuroleptics and psychic indifference
Healy (October 1989 JRSM, p 615) has restated, using modern evidence, the proposal that neuroleptics Cantipsychotics') relieve symptoms of psychosis by inducing a state of psychic indifference", Two comments need to be made. First regarding the lack of efficacyof neuroleptics in paranoia or disorders with overvalued ideas; Healy implies that this observation supports his hypothesis. However, if neuroleptics induce states of psychic indifference then it is very surprising that they are ineffective at reducing the intensity ofdelusions or overvalued ideas in such patients. They are usually intensely concerned about the consequences of their delusion or overvalued idea. There is a major psychic investment in their preoccupation. Psychic indifference would surely result in their symptoms being quenched. Perhaps neuroleptics are effective in such conditions, or at least help to smother the flames; I am not aware of any studies that answer these questions.
Second, Healy adds confusion to his argument by failing to distinguish between behavioural effects of neuroleptics that result from dopamine receptor blockade, and other effects that are probably unrelated to this central characteristic. Only those behavioural and psychic effects ofneuroleptics in man which result from dopamine receptor blockade should be equated with their pharmacologically-defined dopamine antagonist effects on behaviour in animals.
For this purpose Healy's proposition that neuroleptics are especially potent in states of agitation, though partially true, may be irrelevant. This appears to be based on early observations-that neuroleptics are powerful sedatives. These observations of the action of neuroleptics were made exclusively on phenothiazines, their most sedative representatives; indeed chlorpromazine was developed and initially marketed as a sedative to potentiate anaesthetics.
The sedative potency of drugs can be dissociated from their antipsychotic potency. Agitation can be treated effectively with promethazine, which is not generally regarded as antipsychotic and is a very weak dopamine antagonist". On the other hand antipsychotic effects ofneuroleptics are clearly related to blockade of dopamine receptors', Journal of the Royal Society of Medicine Volume 83 July 1990 475 consultants attempted the quiz, but most felt it beneath their dignity -and above their heads.
J P Wilson
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Psychic indifference does seem to be related to dopamine receptor blockade and would appear to be a valuable concept for understanding the antipsychotic effects of neuroleptics. It needs to be well defined and clearly demarcated from other states that decrease arousal and agitation. SIMON We recently saw the first of several patients who had suddenly entered into a state of profound euphoria and since then have heard of31 others who developed a similar condition. In each case the symptoms appeared 5-8 days after close oropharyngeal contact with an affected individual, and transmission of the condition appears to be by deep kissing. An initial mild respiratory illness heralds the appearance of striking euphoric symptoms. There is no hyperactivity or excitement and no dulling of mental activity. Patients continue their daily activities while radiating happiness and contentment. These symptoms persist.
Initial laboratory studies show that the condition is caused by a new human herpes virus (HHV7) which gives persistent infection of salivary glands. It codes for a peptide remarkably similar to endorphin (a known inducer of euphoria, produced normally in the body), which is continuously released from infected cells. The peptide induces no antibody response and tolerance to its euphoric action evidently does not develop.
The news is spreading, and we have already heard of obviously affected individuals cooperating in extensive kissing by strangers who are anxious to acquire the infection. This new virus is unique in conferring benefit rather than disease, and seems
